A 52-year-old male with metastatic melanoma undergoes molecular testing of his tumor tissue to determine eligibility for targeted therapy.
The results reveal a mutation that renders the tumor susceptible to treatment with dabrafenib, a BRAF inhibitor.
Which of the following is the most likely mutation identified?
